Molecular characteristics such as HRD or p53 alteration of ovarian cancer tumours allow high sensitivity to cytotoxic chemotherapy, anti-angiogenetic agent, and PARP inhibitors, a part of molecular deficiencies is known to be restored in some platinum-resistant recurrent ovarian cancers. Here, TP53 is linked to ovarian carcinoma.